What this pack is
Aricept is the brand name in this record; donepezil is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
AriceptGeneric namedonepezil
Mainland China pack-name cue安理申®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The FDA label describes donepezil as a reversible acetylcholinesterase inhibitor and states that its main pharmacologic action is inhibition of acetylcholine hydrolysis. This helps explain why products affecting the cholinergic system need review together; it does not predict an individual's memory change or decide individual strength, adjustment, discontinuation or conversion with another cognition-related medicine.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 安理申®
- International brand name
- Aricept
- Generic name
- donepezil
- Dosage-form class
- Oral film-coated tablets: 5 mg, 10 mg and 23 mg; orally disintegrating tablets: 5 mg and 10 mg (as listed in the current U.S. label)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:安理申®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
5 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v33, published 30 Jun 2026
5 mg; 30-tablet bottle
- Product code
- NDC 62856-245-30
- Form and route
- ARICEPT donepezil hydrochloride film-coated oral tablet · oral
- Container
- bottle
- donepezil hydrochloride
- 5 mglabelled amount per tablet
- Package
- 30 30-tablet bottle
- Labelled appearance
- white · round tablet · imprint ARICEPT / 5
United States label · DailyMed SPL v33, published 30 Jun 2026
10 mg; 30-tablet bottle
- Product code
- NDC 62856-246-30
- Form and route
- ARICEPT donepezil hydrochloride film-coated oral tablet · oral
- Container
- bottle
- donepezil hydrochloride
- 10 mglabelled amount per tablet
- Package
- 30 30-tablet bottle
- Labelled appearance
- yellow · round tablet · imprint ARICEPT / 10
United States label · DailyMed SPL v33, published 30 Jun 2026
23 mg; 30-tablet bottle
- Product code
- NDC 62856-247-30
- Form and route
- ARICEPT donepezil hydrochloride film-coated oral tablet · oral
- Container
- bottle
- donepezil hydrochloride
- 23 mglabelled amount per tablet
- Package
- 30 30-tablet bottle
- Labelled appearance
- reddish · round tablet · imprint ARICEPT / 23
United States label · DailyMed SPL v33, published 30 Jun 2026
5 mg; 30-tablet unit-dose blister carton (10 × 3)
- Product code
- NDC 62856-831-30
- Form and route
- ARICEPT ODT donepezil hydrochloride orally disintegrating tablet · oral
- Container
- unit-dose blister carton
- donepezil hydrochloride
- 5 mglabelled amount per tablet
- Package
- 30 30-tablet unit-dose blister carton (10 × 3)
- Labelled appearance
- white · round tablet · imprint ARICEPT / 5
United States label · DailyMed SPL v33, published 30 Jun 2026
10 mg; 30-tablet unit-dose blister carton (10 × 3)
- Product code
- NDC 62856-832-30
- Form and route
- ARICEPT ODT donepezil hydrochloride orally disintegrating tablet · oral
- Container
- unit-dose blister carton
- donepezil hydrochloride
- 10 mglabelled amount per tablet
- Package
- 30 30-tablet unit-dose blister carton (10 × 3)
- Labelled appearance
- yellow · round tablet · imprint ARICEPT / 10
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ARICEPT label reading: tablets, ODT and 23 mg must be checked together
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses Eisai's current U.S. DailyMed label as a reading entry point. It helps check ARICEPT tablets, orally disintegrating tablets, labelled amount per tablet, NDC and package; it does not provide an individual start, increase, stop, switch or splitting plan.
- First check ARICEPT, donepezil, tablet or orally disintegrating tablet, labelled strength per unit and target market. A “5”, “10” or “23” alone does not say how a person should use it or prove interchangeability with another pack.
- The current U.S. label distinguishes 5, 10 and 23 mg tablets and 5 and 10 mg orally disintegrating tablets; it states that the 23 mg tablet should not be split, crushed or chewed. Another market or product version needs checking against the current label for that exact product.
- The label identifies issues that may require attention involving heart rate, gastrointestinal effects, weight, anaesthesia and combinations with anticholinergic or other cholinergic medicines. When multiple memory, sleep, cold, pain or bladder products are at home, bring the complete list to a pharmacist rather than self-combining, substituting or stopping.
- For fainting, a marked heart-rate concern, persistent vomiting/dehydration, black stools or another acute symptom, seek timely medical assessment; a webpage and historical label cannot replace urgent judgement.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. ARICEPT / ARICEPT ODT public label (Eisai; SPL v33, published 30 Jun 2026) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Aricept (donepezil). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Aricept is the brand in this record and donepezil is the active-ingredient name. Check both with the dosage form (Oral film-coated tablets: 5 mg, 10 mg and 23 mg; orally disintegrating tablets: 5 mg and 10 mg (as listed in the current U.S. label)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How donepezil works: it reversibly inhibits acetylcholinesterase
- A shared effect on the cholinergic system does not make donepezil self-combinable, cancellable, substitutable or alternatable with another memory medicine, bladder medicine, allergy/cold product or supplement. Every prescription, OTC product and supplement should be reviewed item by item with a pharmacist or prescribing team.
- Mechanism cannot convert 5, 10 or 23 mg, or tablet/ODT form, into an individual's use rule, nor show that one number “suits” someone better. Exact form, strength, prior circumstances, other medicines and the current label must be checked together.
- Heart-rate changes, fainting, gastrointestinal symptoms, weight change or a new behaviour/awareness concern cannot be self-managed from a mechanism page. With an acute symptom or a plan to change any cognition-related medicine, use timely local professional support.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. ARICEPT / ARICEPT ODT public label (Eisai; SPL v33, published 30 Jun 2026) ↗reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Ariceptdonepezil
This page links to public primary-source material for Aricept. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The current ARICEPT / ARICEPT ODT label lists Initial U.S. Approval: 1996; it does not establish status in another market.
DailyMed (NLM): current U.S. ARICEPT / ARICEPT ODT public label (Eisai; SPL v33, published 30 Jun 2026) ↗Current SPL v33 published on DailyMed
DailyMed's media listing shows current ARICEPT / ARICEPT ODT SPL v33 published on 30 Jun 2026 and includes the five exact package panels shown here. The date and images do not establish actual marketing, stock or another package/market status.
DailyMed (NLM): current U.S. ARICEPT / ARICEPT ODT public label (Eisai; SPL v33, published 30 Jun 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current label and five exact package panels linkedThe display panels correspond separately to the specified NDCs for 5 mg, 10 mg and 23 mg tablets and 5 mg and 10 mg ARICEPT ODT; they do not establish actual marketing, stock, individual use or another-package status.
Mainland China, EU, Japan and other markets
Market record not establishedNo local trade name, approval, package, supply, originator relationship or interchangeability is inferred from the U.S. label.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 安理申®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Can ARICEPT and ARICEPT ODT be self-switched just because the milligrams match?
No. Tablets and orally disintegrating tablets are different exact product forms. A shared generic name or number does not establish self-switching, splitting, crushing, chewing or adjustment. Have a pharmacist or prescribing team check the actual package, NDC and complete medicine list.
Can 23 mg be self-assembled from lower-strength tablets?
No. This page shows label identity only. The current U.S. label lists the 23 mg tablet separately and says it should not be split, crushed or chewed. This page does not convert package numbers into a personal tablet count or switching plan.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.